Domperidone on the Composition of Preterm Breastmilk Using a Human Milk Mid-infrared Spectroscopy Analyzer
Launched by CENTRO HOSPITALAR DE LISBOA CENTRAL · Feb 11, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study design: This is a single-center observational study based on a convenience cohort of lactating women who have delivered before 37 weeks gestation.
Study period: A consecutive recruitment of participants will be scheduled over 12 months (from February 2, 2025), according to the availability of the observer (M.C.) in charge of the analysis of breast milk in the unit, performed weekly on a routine basis, in order to be fortified if necessary (Cardoso 2023).
Settings: Neonatal Intensive Care Unit (NICU) and Human Milk Bank at Maternidade Dr. Alfredo da Costa, Unidade Local de Saúde São ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Lactating women who have delivered prematurely using domperidone as a galactagogue, who will consent to participate, and who are not taking other substances or medications acting as galactagogues
- Exclusion Criteria:
- • Lactating women do not agree to participate
- • Lactating women use domperidone not as a galactagogue
- • Lactating women currently or previously taking other substances or medications acting as galactagogues
- • Lactating women taking medications that may alter the effect (such as ranitidine) or interact with domperidone (such as haloperidol)
- • Lactating women who have the diagnosis of mastitis
- • Lactating women with debilitating chronic illness
About Centro Hospitalar De Lisboa Central
Centro Hospitalar de Lisboa Central (CHLC) is a leading healthcare institution in Portugal, dedicated to providing high-quality medical care and advancing clinical research. As a prominent sponsor of clinical trials, CHLC plays a crucial role in the development of innovative therapies and treatments across various medical fields. The hospital is committed to fostering collaborations with academic institutions and industry partners, ensuring rigorous adherence to ethical standards and regulatory guidelines. With a multidisciplinary team of experienced researchers and healthcare professionals, CHLC aims to enhance patient outcomes and contribute to the global body of medical knowledge through its comprehensive clinical research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lisboa, , Portugal
Patients applied
Trial Officials
Daniel Virella, MD, MSc
Study Chair
Unidade Local de Saúde São José
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported